Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obstetrics | 7 | 2017 | 16 | 3.560 |
Why?
|
| Clinical Competence | 11 | 2017 | 307 | 2.880 |
Why?
|
| Pregnancy | 20 | 2018 | 815 | 1.740 |
Why?
|
| Delivery, Obstetric | 3 | 2017 | 50 | 1.690 |
Why?
|
| Patient Simulation | 3 | 2015 | 30 | 1.450 |
Why?
|
| Internship and Residency | 4 | 2017 | 283 | 1.300 |
Why?
|
| Clinical Clerkship | 3 | 2016 | 41 | 1.190 |
Why?
|
| Gynecology | 3 | 2017 | 15 | 1.190 |
Why?
|
| Ultrasonography, Interventional | 2 | 2017 | 51 | 1.180 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2017 | 22 | 1.170 |
Why?
|
| Acetaminophen | 2 | 2016 | 18 | 1.110 |
Why?
|
| Students, Medical | 2 | 2017 | 121 | 1.060 |
Why?
|
| Fetus | 2 | 2015 | 78 | 1.030 |
Why?
|
| Models, Anatomic | 4 | 2015 | 38 | 0.850 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2011 | 13 | 0.790 |
Why?
|
| Pregnancy Complications | 4 | 2018 | 80 | 0.770 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 41 | 0.770 |
Why?
|
| Neutrophils | 2 | 2011 | 102 | 0.740 |
Why?
|
| Female | 23 | 2018 | 18173 | 0.730 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 17 | 0.720 |
Why?
|
| Abnormalities, Multiple | 2 | 2017 | 24 | 0.640 |
Why?
|
| Swine | 2 | 2015 | 201 | 0.640 |
Why?
|
| Adult | 15 | 2018 | 8426 | 0.620 |
Why?
|
| Educational Status | 1 | 2017 | 164 | 0.600 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 6 | 0.590 |
Why?
|
| Family Practice | 1 | 2017 | 46 | 0.590 |
Why?
|
| Fetal Blood | 1 | 2016 | 35 | 0.570 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2018 | 13 | 0.570 |
Why?
|
| Cerclage, Cervical | 2 | 2013 | 6 | 0.560 |
Why?
|
| Labor Stage, First | 1 | 2015 | 6 | 0.550 |
Why?
|
| Educational Measurement | 4 | 2017 | 111 | 0.540 |
Why?
|
| Fetal Movement | 1 | 2015 | 1 | 0.540 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 16 | 0.530 |
Why?
|
| Humans | 22 | 2018 | 29123 | 0.530 |
Why?
|
| Abortion, Induced | 1 | 2015 | 5 | 0.520 |
Why?
|
| Radiology | 1 | 2015 | 37 | 0.520 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2015 | 84 | 0.500 |
Why?
|
| Cesarean Section | 3 | 2011 | 82 | 0.500 |
Why?
|
| Lung Diseases | 1 | 2014 | 45 | 0.480 |
Why?
|
| RNA, Messenger | 3 | 2011 | 514 | 0.470 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 45 | 0.460 |
Why?
|
| Lung | 1 | 2014 | 233 | 0.430 |
Why?
|
| Analgesics | 2 | 2011 | 126 | 0.430 |
Why?
|
| Surgical Stapling | 1 | 2011 | 11 | 0.420 |
Why?
|
| Receptors, Opioid, delta | 4 | 2004 | 17 | 0.410 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2011 | 3 | 0.400 |
Why?
|
| Blood Cells | 1 | 2010 | 9 | 0.390 |
Why?
|
| Curriculum | 3 | 2017 | 196 | 0.380 |
Why?
|
| Pre-Eclampsia | 1 | 2011 | 53 | 0.370 |
Why?
|
| Pregnancy Outcome | 2 | 2010 | 52 | 0.370 |
Why?
|
| Placenta | 1 | 2010 | 63 | 0.370 |
Why?
|
| Fontan Procedure | 1 | 2009 | 2 | 0.360 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 28 | 0.350 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 21 | 0.350 |
Why?
|
| Pain, Postoperative | 1 | 2011 | 174 | 0.350 |
Why?
|
| Models, Animal | 3 | 2015 | 160 | 0.340 |
Why?
|
| Prospective Studies | 3 | 2017 | 2021 | 0.300 |
Why?
|
| Animals | 10 | 2015 | 7299 | 0.290 |
Why?
|
| Receptors, Opioid, mu | 2 | 2004 | 51 | 0.280 |
Why?
|
| Analgesics, Opioid | 3 | 2004 | 239 | 0.240 |
Why?
|
| Gestational Age | 2 | 2016 | 96 | 0.230 |
Why?
|
| Uterine Cervical Incompetence | 2 | 2013 | 3 | 0.230 |
Why?
|
| Morphine Dependence | 1 | 2002 | 3 | 0.230 |
Why?
|
| Enkephalins | 1 | 2002 | 9 | 0.230 |
Why?
|
| Chorionic Villi Sampling | 2 | 2013 | 2 | 0.230 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2003 | 24 | 0.230 |
Why?
|
| Protein Precursors | 1 | 2002 | 22 | 0.220 |
Why?
|
| Morphine | 1 | 2002 | 57 | 0.220 |
Why?
|
| Male | 8 | 2017 | 17815 | 0.210 |
Why?
|
| Brain | 3 | 2004 | 930 | 0.210 |
Why?
|
| Uterine Diseases | 1 | 2018 | 15 | 0.170 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 493 | 0.160 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2017 | 3 | 0.160 |
Why?
|
| Fetal Death | 1 | 2017 | 6 | 0.160 |
Why?
|
| Checklist | 1 | 2017 | 35 | 0.150 |
Why?
|
| Colon | 1 | 2017 | 56 | 0.150 |
Why?
|
| Gelatin | 1 | 2017 | 27 | 0.150 |
Why?
|
| Term Birth | 1 | 2016 | 3 | 0.150 |
Why?
|
| Young Adult | 2 | 2015 | 2402 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2016 | 46 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2017 | 69 | 0.140 |
Why?
|
| Urinary Bladder | 1 | 2017 | 165 | 0.140 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 3 | 2004 | 5 | 0.130 |
Why?
|
| Linear Models | 1 | 2016 | 426 | 0.130 |
Why?
|
| Respiration | 1 | 2015 | 26 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 162 | 0.130 |
Why?
|
| Physicians | 1 | 2017 | 134 | 0.130 |
Why?
|
| Teaching | 1 | 2015 | 55 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2015 | 175 | 0.130 |
Why?
|
| Models, Biological | 1 | 2017 | 373 | 0.130 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2013 | 2 | 0.120 |
Why?
|
| Amniocentesis | 1 | 2013 | 2 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 721 | 0.110 |
Why?
|
| Mice | 6 | 2004 | 2370 | 0.110 |
Why?
|
| Perinatology | 1 | 2012 | 2 | 0.110 |
Why?
|
| Steel | 1 | 2011 | 2 | 0.100 |
Why?
|
| Mice, Knockout | 5 | 2004 | 425 | 0.100 |
Why?
|
| Polyglycolic Acid | 1 | 2011 | 32 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 532 | 0.100 |
Why?
|
| Sutures | 1 | 2011 | 19 | 0.100 |
Why?
|
| Absorbable Implants | 1 | 2011 | 24 | 0.100 |
Why?
|
| North Carolina | 1 | 2015 | 1423 | 0.100 |
Why?
|
| Pregnancy Trimesters | 1 | 2010 | 3 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2015 | 1688 | 0.100 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 14 | 0.100 |
Why?
|
| Rectus Abdominis | 1 | 2010 | 2 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 172 | 0.100 |
Why?
|
| Hematoma | 1 | 2010 | 23 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 143 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2010 | 40 | 0.090 |
Why?
|
| Wound Healing | 1 | 2011 | 182 | 0.090 |
Why?
|
| Naloxone | 3 | 2004 | 23 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 374 | 0.090 |
Why?
|
| Prognosis | 1 | 2014 | 1362 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 210 | 0.090 |
Why?
|
| Obstetric Labor, Premature | 1 | 2009 | 5 | 0.090 |
Why?
|
| Autoradiography | 3 | 2004 | 47 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2011 | 859 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1219 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 481 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2009 | 599 | 0.080 |
Why?
|
| Drug Tolerance | 2 | 2002 | 36 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 2109 | 0.070 |
Why?
|
| Thymus Gland | 1 | 2004 | 15 | 0.060 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2004 | 40 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 114 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3112 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 9 | 0.060 |
Why?
|
| Sulfur Radioisotopes | 1 | 2003 | 9 | 0.060 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2003 | 18 | 0.060 |
Why?
|
| N-Methylaspartate | 1 | 2002 | 12 | 0.060 |
Why?
|
| Convulsants | 1 | 2002 | 2 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2002 | 17 | 0.060 |
Why?
|
| Adolescent | 1 | 2010 | 3255 | 0.060 |
Why?
|
| Naltrexone | 1 | 2002 | 38 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 53 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2002 | 38 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2002 | 139 | 0.050 |
Why?
|
| Narcotic Antagonists | 3 | 2004 | 50 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2018 | 21 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 2018 | 24 | 0.040 |
Why?
|
| Education, Medical | 1 | 2012 | 67 | 0.030 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 2 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2010 | 19 | 0.020 |
Why?
|
| Endorphins | 1 | 2004 | 1 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2004 | 6 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 9 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 5 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 30 | 0.020 |
Why?
|
| Cell Count | 1 | 2004 | 50 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2004 | 80 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2004 | 38 | 0.020 |
Why?
|
| Protein Binding | 1 | 2004 | 199 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 160 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2004 | 172 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2004 | 454 | 0.010 |
Why?
|
| Benzomorphans | 1 | 2002 | 5 | 0.010 |
Why?
|
| Benzylidene Compounds | 1 | 2002 | 6 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 38 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 125 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 2002 | 28 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 54 | 0.010 |
Why?
|
| Benzamides | 1 | 2002 | 54 | 0.010 |
Why?
|
| Piperazines | 1 | 2002 | 56 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 436 | 0.010 |
Why?
|
| Middle Aged | 1 | 2012 | 10834 | 0.010 |
Why?
|